GlassScriptPhysician profile
Alon A Steinberg
NPI 1740282862
$29,107.10
in general payments reported to CMS, 2019-2025
51 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,641 · 2021: $1,510 · 2022: $1,586 · 2023: $2,211 · 2024: $1,908 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,248.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14,064.72 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $3,742.07 | 2019-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Rotapro |
| Novartis Pharmaceuticals Corporation | $1,677.09 | 2019-2025 | |
| Amgen INC. | $1,576.93 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,068.17 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $744.66 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $641.84 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Pfizer INC. | $634.26 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $618.43 | 2019-2025 | Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $585.50 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $479.99 | 2019-2025 | Impella |
| Abbott Laboratories | $257.55 | 2019-2024 | Gallant, Aveir, Mitraclip |
| Kiniksa Pharmaceuticals International, Plc | $251.26 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $197.43 | 2019-2025 | Onpattro, Amvuttra |
| Sanofi-Aventis U.S. LLC | $186.16 | 2019-2022 |
Show all 48 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alon Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.